Big Pharma's antibody drugs for asthma show benefits but cost 50% too much: ICER
admin 26th September 2018 Uncategorised 0Xolair, Nucala, Cinqair, Fasenra and Dupixent are better than traditional treatments for moderate to severe asthma, but they still cost too much, a U.S. drug cost watchdog says. More than 50% too much, in fact.
More: Big Pharma's antibody drugs for asthma show benefits but cost 50% too much: ICER
Source: fierce